Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients
To compare the effects of miglitol [an alpha‐glucosidase inhibitor (AGI) absorbed in the intestine] and voglibose (an AGI not absorbed) on plasma glucagon‐like peptide‐1 (GLP‐1) and gastric inhibitory polypeptide (GIP) levels, 26 and 24 Japanese type 2 diabetic patients were randomly assigned to rec...
Gespeichert in:
| Veröffentlicht in: | Diabetes, obesity & metabolism obesity & metabolism, 2012-03, Vol.14 (3), p.283-287 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 287 |
|---|---|
| container_issue | 3 |
| container_start_page | 283 |
| container_title | Diabetes, obesity & metabolism |
| container_volume | 14 |
| creator | Narita, T. Yokoyama, H. Yamashita, R. Sato, T. Hosoba, M. Morii, T. Fujita, H. Tsukiyama, K. Yamada, Y. |
| description | To compare the effects of miglitol [an alpha‐glucosidase inhibitor (AGI) absorbed in the intestine] and voglibose (an AGI not absorbed) on plasma glucagon‐like peptide‐1 (GLP‐1) and gastric inhibitory polypeptide (GIP) levels, 26 and 24 Japanese type 2 diabetic patients were randomly assigned to receive miglitol or voglibose, respectively. After 12‐week administration of both drugs, during 2‐h meal tolerance test, plasma glucose, serum insulin and total GIP were significantly decreased and active GLP‐1 was significantly increased. Miglitol group showed a significantly lower total GIP level than voglibose group. Miglitol, but not voglibose, significantly reduced body weight (BW). In all participants, the relative change in BW was positively correlated with that of insulin significantly and of GIP with a weak tendency, but not of GLP‐1. In conclusion, both drugs can enhance postprandial GLP‐1 responses and reduce GIP responses. The significant BW reduction by miglitol might be attributable to its strong GIP‐reducing efficacy. |
| doi_str_mv | 10.1111/j.1463-1326.2011.01526.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_921141079</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>921141079</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5006-f5f46a4723d5e632e384c58fa757a0beb7fca0bd549660cca3ff259ab98b0d9f3</originalsourceid><addsrcrecordid>eNqNUUtv1DAQjhCIPuAvIEscOGXxO8mBA1qgpS300CKOluOMwdskTm0v3f1N_Emc3bIHTsxlZvQ9ZqSvKBDBC5Lr7WpBuGQlYVQuKCZkgYnI4-ZJcXwAnu5mWtYNpkfFSYwrjDFndfW8OKIUC0IkPS5-L_0w6eCiHyPyFqWfgMBaMGm3Elo-ANwh3Q1udDEFnZwfZ2RwP3qXfI_02KFfPi-tj4AyOFsEiFN2hJ3J1Os4aORGEyC5fEfbBAHp7LGBDg2g-wyiCz3pEbJH2k6AKOqcbjPfoCkfhTHFF8Uzq_sILx_7afHt08fb5Xl5dX32efn-qjQCY1laYbnUvKKsEyAZBVZzI2qrK1Fp3EJbWZN7J3gjJTZGM2upaHTb1C3uGstOizd73yn4-zXEpAYXDfR9fs-vo2ooIZzgqsnM1_8wV34dxvycYlg0nEtBSWbVe5YJPsYAVk3BDTpsFcFqzlOt1BybmmNTc55ql6faZOmrxwPrdoDuIPwbYCa82xMeXA_b_zZWH66_zFPWl3t9Dhc2B70Od0pWrBLq-9czdXl7eXNR8xtVsz_dkb_f</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3059446521</pqid></control><display><type>article</type><title>Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Narita, T. ; Yokoyama, H. ; Yamashita, R. ; Sato, T. ; Hosoba, M. ; Morii, T. ; Fujita, H. ; Tsukiyama, K. ; Yamada, Y.</creator><creatorcontrib>Narita, T. ; Yokoyama, H. ; Yamashita, R. ; Sato, T. ; Hosoba, M. ; Morii, T. ; Fujita, H. ; Tsukiyama, K. ; Yamada, Y.</creatorcontrib><description>To compare the effects of miglitol [an alpha‐glucosidase inhibitor (AGI) absorbed in the intestine] and voglibose (an AGI not absorbed) on plasma glucagon‐like peptide‐1 (GLP‐1) and gastric inhibitory polypeptide (GIP) levels, 26 and 24 Japanese type 2 diabetic patients were randomly assigned to receive miglitol or voglibose, respectively. After 12‐week administration of both drugs, during 2‐h meal tolerance test, plasma glucose, serum insulin and total GIP were significantly decreased and active GLP‐1 was significantly increased. Miglitol group showed a significantly lower total GIP level than voglibose group. Miglitol, but not voglibose, significantly reduced body weight (BW). In all participants, the relative change in BW was positively correlated with that of insulin significantly and of GIP with a weak tendency, but not of GLP‐1. In conclusion, both drugs can enhance postprandial GLP‐1 responses and reduce GIP responses. The significant BW reduction by miglitol might be attributable to its strong GIP‐reducing efficacy.</description><identifier>ISSN: 1462-8902</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/j.1463-1326.2011.01526.x</identifier><identifier>PMID: 22051162</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>1-Deoxynojirimycin - administration & dosage ; 1-Deoxynojirimycin - analogs & derivatives ; 1-Deoxynojirimycin - pharmacology ; Asian Continental Ancestry Group ; Body weight ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - metabolism ; Drug Administration Schedule ; Drug tolerance ; Female ; Gastric Inhibitory Polypeptide - drug effects ; GIP ; GLP-1 ; Glucagon ; Glucagon-Like Peptide 1 - drug effects ; Glucose tolerance ; Humans ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - pharmacology ; incretin ; Incretins - blood ; Inositol - administration & dosage ; Inositol - analogs & derivatives ; Inositol - pharmacology ; Insulin ; Male ; Middle Aged ; Miglitol ; Obesity - blood ; Obesity - drug therapy ; Obesity - metabolism ; Postprandial Period ; voglibose</subject><ispartof>Diabetes, obesity & metabolism, 2012-03, Vol.14 (3), p.283-287</ispartof><rights>2011 Blackwell Publishing Ltd</rights><rights>2011 Blackwell Publishing Ltd.</rights><rights>Copyright Wiley Subscription Services, Inc. Mar 2012</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5006-f5f46a4723d5e632e384c58fa757a0beb7fca0bd549660cca3ff259ab98b0d9f3</citedby><cites>FETCH-LOGICAL-c5006-f5f46a4723d5e632e384c58fa757a0beb7fca0bd549660cca3ff259ab98b0d9f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1463-1326.2011.01526.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1463-1326.2011.01526.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22051162$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Narita, T.</creatorcontrib><creatorcontrib>Yokoyama, H.</creatorcontrib><creatorcontrib>Yamashita, R.</creatorcontrib><creatorcontrib>Sato, T.</creatorcontrib><creatorcontrib>Hosoba, M.</creatorcontrib><creatorcontrib>Morii, T.</creatorcontrib><creatorcontrib>Fujita, H.</creatorcontrib><creatorcontrib>Tsukiyama, K.</creatorcontrib><creatorcontrib>Yamada, Y.</creatorcontrib><title>Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients</title><title>Diabetes, obesity & metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description>To compare the effects of miglitol [an alpha‐glucosidase inhibitor (AGI) absorbed in the intestine] and voglibose (an AGI not absorbed) on plasma glucagon‐like peptide‐1 (GLP‐1) and gastric inhibitory polypeptide (GIP) levels, 26 and 24 Japanese type 2 diabetic patients were randomly assigned to receive miglitol or voglibose, respectively. After 12‐week administration of both drugs, during 2‐h meal tolerance test, plasma glucose, serum insulin and total GIP were significantly decreased and active GLP‐1 was significantly increased. Miglitol group showed a significantly lower total GIP level than voglibose group. Miglitol, but not voglibose, significantly reduced body weight (BW). In all participants, the relative change in BW was positively correlated with that of insulin significantly and of GIP with a weak tendency, but not of GLP‐1. In conclusion, both drugs can enhance postprandial GLP‐1 responses and reduce GIP responses. The significant BW reduction by miglitol might be attributable to its strong GIP‐reducing efficacy.</description><subject>1-Deoxynojirimycin - administration & dosage</subject><subject>1-Deoxynojirimycin - analogs & derivatives</subject><subject>1-Deoxynojirimycin - pharmacology</subject><subject>Asian Continental Ancestry Group</subject><subject>Body weight</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Drug Administration Schedule</subject><subject>Drug tolerance</subject><subject>Female</subject><subject>Gastric Inhibitory Polypeptide - drug effects</subject><subject>GIP</subject><subject>GLP-1</subject><subject>Glucagon</subject><subject>Glucagon-Like Peptide 1 - drug effects</subject><subject>Glucose tolerance</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>incretin</subject><subject>Incretins - blood</subject><subject>Inositol - administration & dosage</subject><subject>Inositol - analogs & derivatives</subject><subject>Inositol - pharmacology</subject><subject>Insulin</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Miglitol</subject><subject>Obesity - blood</subject><subject>Obesity - drug therapy</subject><subject>Obesity - metabolism</subject><subject>Postprandial Period</subject><subject>voglibose</subject><issn>1462-8902</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUUtv1DAQjhCIPuAvIEscOGXxO8mBA1qgpS300CKOluOMwdskTm0v3f1N_Emc3bIHTsxlZvQ9ZqSvKBDBC5Lr7WpBuGQlYVQuKCZkgYnI4-ZJcXwAnu5mWtYNpkfFSYwrjDFndfW8OKIUC0IkPS5-L_0w6eCiHyPyFqWfgMBaMGm3Elo-ANwh3Q1udDEFnZwfZ2RwP3qXfI_02KFfPi-tj4AyOFsEiFN2hJ3J1Os4aORGEyC5fEfbBAHp7LGBDg2g-wyiCz3pEbJH2k6AKOqcbjPfoCkfhTHFF8Uzq_sILx_7afHt08fb5Xl5dX32efn-qjQCY1laYbnUvKKsEyAZBVZzI2qrK1Fp3EJbWZN7J3gjJTZGM2upaHTb1C3uGstOizd73yn4-zXEpAYXDfR9fs-vo2ooIZzgqsnM1_8wV34dxvycYlg0nEtBSWbVe5YJPsYAVk3BDTpsFcFqzlOt1BybmmNTc55ql6faZOmrxwPrdoDuIPwbYCa82xMeXA_b_zZWH66_zFPWl3t9Dhc2B70Od0pWrBLq-9czdXl7eXNR8xtVsz_dkb_f</recordid><startdate>201203</startdate><enddate>201203</enddate><creator>Narita, T.</creator><creator>Yokoyama, H.</creator><creator>Yamashita, R.</creator><creator>Sato, T.</creator><creator>Hosoba, M.</creator><creator>Morii, T.</creator><creator>Fujita, H.</creator><creator>Tsukiyama, K.</creator><creator>Yamada, Y.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201203</creationdate><title>Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients</title><author>Narita, T. ; Yokoyama, H. ; Yamashita, R. ; Sato, T. ; Hosoba, M. ; Morii, T. ; Fujita, H. ; Tsukiyama, K. ; Yamada, Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5006-f5f46a4723d5e632e384c58fa757a0beb7fca0bd549660cca3ff259ab98b0d9f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>1-Deoxynojirimycin - administration & dosage</topic><topic>1-Deoxynojirimycin - analogs & derivatives</topic><topic>1-Deoxynojirimycin - pharmacology</topic><topic>Asian Continental Ancestry Group</topic><topic>Body weight</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Drug Administration Schedule</topic><topic>Drug tolerance</topic><topic>Female</topic><topic>Gastric Inhibitory Polypeptide - drug effects</topic><topic>GIP</topic><topic>GLP-1</topic><topic>Glucagon</topic><topic>Glucagon-Like Peptide 1 - drug effects</topic><topic>Glucose tolerance</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>incretin</topic><topic>Incretins - blood</topic><topic>Inositol - administration & dosage</topic><topic>Inositol - analogs & derivatives</topic><topic>Inositol - pharmacology</topic><topic>Insulin</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Miglitol</topic><topic>Obesity - blood</topic><topic>Obesity - drug therapy</topic><topic>Obesity - metabolism</topic><topic>Postprandial Period</topic><topic>voglibose</topic><toplevel>online_resources</toplevel><creatorcontrib>Narita, T.</creatorcontrib><creatorcontrib>Yokoyama, H.</creatorcontrib><creatorcontrib>Yamashita, R.</creatorcontrib><creatorcontrib>Sato, T.</creatorcontrib><creatorcontrib>Hosoba, M.</creatorcontrib><creatorcontrib>Morii, T.</creatorcontrib><creatorcontrib>Fujita, H.</creatorcontrib><creatorcontrib>Tsukiyama, K.</creatorcontrib><creatorcontrib>Yamada, Y.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes, obesity & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Narita, T.</au><au>Yokoyama, H.</au><au>Yamashita, R.</au><au>Sato, T.</au><au>Hosoba, M.</au><au>Morii, T.</au><au>Fujita, H.</au><au>Tsukiyama, K.</au><au>Yamada, Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients</atitle><jtitle>Diabetes, obesity & metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2012-03</date><risdate>2012</risdate><volume>14</volume><issue>3</issue><spage>283</spage><epage>287</epage><pages>283-287</pages><issn>1462-8902</issn><eissn>1463-1326</eissn><abstract>To compare the effects of miglitol [an alpha‐glucosidase inhibitor (AGI) absorbed in the intestine] and voglibose (an AGI not absorbed) on plasma glucagon‐like peptide‐1 (GLP‐1) and gastric inhibitory polypeptide (GIP) levels, 26 and 24 Japanese type 2 diabetic patients were randomly assigned to receive miglitol or voglibose, respectively. After 12‐week administration of both drugs, during 2‐h meal tolerance test, plasma glucose, serum insulin and total GIP were significantly decreased and active GLP‐1 was significantly increased. Miglitol group showed a significantly lower total GIP level than voglibose group. Miglitol, but not voglibose, significantly reduced body weight (BW). In all participants, the relative change in BW was positively correlated with that of insulin significantly and of GIP with a weak tendency, but not of GLP‐1. In conclusion, both drugs can enhance postprandial GLP‐1 responses and reduce GIP responses. The significant BW reduction by miglitol might be attributable to its strong GIP‐reducing efficacy.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>22051162</pmid><doi>10.1111/j.1463-1326.2011.01526.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-8902 |
| ispartof | Diabetes, obesity & metabolism, 2012-03, Vol.14 (3), p.283-287 |
| issn | 1462-8902 1463-1326 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_921141079 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | 1-Deoxynojirimycin - administration & dosage 1-Deoxynojirimycin - analogs & derivatives 1-Deoxynojirimycin - pharmacology Asian Continental Ancestry Group Body weight Diabetes Diabetes mellitus Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Drug Administration Schedule Drug tolerance Female Gastric Inhibitory Polypeptide - drug effects GIP GLP-1 Glucagon Glucagon-Like Peptide 1 - drug effects Glucose tolerance Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - pharmacology incretin Incretins - blood Inositol - administration & dosage Inositol - analogs & derivatives Inositol - pharmacology Insulin Male Middle Aged Miglitol Obesity - blood Obesity - drug therapy Obesity - metabolism Postprandial Period voglibose |
| title | Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T08%3A59%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparisons%20of%20the%20effects%20of%2012-week%20administration%20of%20miglitol%20and%20voglibose%20on%20the%20responses%20of%20plasma%20incretins%20after%20a%20mixed%20meal%20in%20Japanese%20type%202%20diabetic%20patients&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=Narita,%20T.&rft.date=2012-03&rft.volume=14&rft.issue=3&rft.spage=283&rft.epage=287&rft.pages=283-287&rft.issn=1462-8902&rft.eissn=1463-1326&rft_id=info:doi/10.1111/j.1463-1326.2011.01526.x&rft_dat=%3Cproquest_cross%3E921141079%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3059446521&rft_id=info:pmid/22051162&rfr_iscdi=true |